

April 26, 2010

Dear Doctor,

Recently, CSL Behring released Hizentra; a new FDA approved 20% subcutaneous immune globulin which will replace their current product, Vivaglobin, a 16% subcutaneous immune globulin. Our understanding is that Vivaglobin will be phased-out over the next 12 to 18 months. *You are receiving this letter because we are currently treating at least one of your patients with Vivaglobin and want to be sure we keep you informed of information being disseminated.*

In an effort to provide the highest level of service you and your patient(s) have come to expect from BioRx, we have provided the enclosed communication that was sent to current Vivaglobin consumers we service. The letter is self explanatory; please review it at your convenience.

With the availability of information and excitement that surrounds new product introductions, we felt it was important for us (as their pharmacy provider) to send them this letter. Additionally, we reinforced the importance of discussing their care plans with you.

I have asked your BioRx field representative to contact you personally as soon as they are able regarding this matter and discuss a mutually agreeable plan to transition your Vivaglobin patients to Hizentra over the phase-out period.

In the meantime, if you have any questions or I can be of any help please email me at the address below.

Sincerely,

Jay Grady

Jay Grady
Director, Immunotherapy Services
BioRx
jgrady@BioRx.net